MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
LQDA stock logo

LQDA

Liquidia Corporation

$28.64
0.65
 (2.32%)
Exchange:  NASDAQ
Market Cap:  2.547B
Shares Outstanding:  5.088M
Delayed data
Calculate LQDA Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – PharmaceuticalsView industry performance
   
CEO:  Roger A. Jeffs
Full Time Employees:  216
Address: 
419 Davis Drive
Morrisville
NC
27560
US
Website:  https://www.liquidia.com
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation’s main office is located in Morrisville, North Carolina.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
LQLQDA logoLQDALiquidia Corporation2.5B43.615.246.9%
PBPBH logoPBHPrestige Consumer Healthcare Inc.2.1B13.09.94.8%
HEHELP logoHELPCybin Inc. Common Stock725.2M——-70.8%
CECELG-RI logoCELG-RIBristol-Myers Squibb Company Ce263.9M—0.013.6%
HIHITI logoHITIHigh Tide Inc.231.1M—23.49.7%
POPOM logoPOMPOMDOCTOR Ltd31.5M——44.0%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/11 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue17,48813,996158,320
Gross Profit14,6008,117145,078
EBITDA-70,051-115,711-43,224
Operating Income-73,384-121,294-51,376
Net Income-78,502-130,394-68,924

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets118,332230,313327,934
Total Liabilities71,039153,038283,186
Total Stockholders Equity47,29377,27544,748
Total Debt49,536122,39064,992
Cash and Cash Equivalents83,679176,479190,680

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-41,564-93,4220
Capital Expenditure-1,290-4,9490
Free Cash Flow-42,854-98,3710
Net Income-78,502-130,3940
Net Change in Cash-9,60492,80017,705

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)1,166,564.125Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,766,395.801Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)1,489,374Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)643,745.978Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)1,040,707.202Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)857,377.349Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)430,202.566Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)743,801.933Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)598,971.349Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)3,082,347.843Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)4,667,249.892Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)3,935,290.515Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)6.960Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)8.640Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)5Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
13.996M  ?P/S
 (TTM)
: 
13.5
?Net Income
 (TTM)
: 
-130394000  ?P/E
 (TTM)
: 
43.61
?Enterprise Value
 (TTM)
: 
5.93B  ?EV/FCF
 (TTM)
: 
98
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
149.65%  ?ROIC
 (TTM)
: 
46.86%
?Net Debt
 (TTM)
: 
-169476000  ?Debt/Equity
 (TTM)
: 
0.66
?P/B
 (TTM)
: 
31.17  ?Current Ratio
 (TTM)
: 
2.31

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
15.15Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about LQDA valuation

Is Liquidia Corporation (LQDA) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Liquidia Corporation (LQDA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is LQDA a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether LQDA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is LQDA’s P/E ratio?

You can see LQDA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for LQDA?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is LQDA a good long-term investment?

Whether LQDA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

LQDA

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

2.32
MARKETSnap

Trading Metrics:

Open: 26.69   Previous Close: 27.99
Day Low: 26.31   Day High: 29.15
Year Low: 21.91   Year High: 93.61
Price Avg 50: 73.18   Price Avg 200: 54.23
Volume: 8.39M   Average Volume: 2.25M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
01-10-2026 14:31
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
30-09-2026 19:09
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
30-09-2026 13:20
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
California State Teachers Retirement System Acquires 5,835,156 Shares of Liquidia Corporation $LQDA
15-09-2026 03:26
California State Teachers Retirement System Acquires 5,835,156 Shares of Liquidia Corporation $LQDA
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
11-09-2026 15:26
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
10-09-2026 14:40
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • Learn
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read